Safety Reading Notes

Read safety context beside the research guide.

The Cognition and memory source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 26912385

PubMed For Dummies Article

Cognition and memory Evidence Review: the long-form source walk-through

Quick read
  • Cognition and memory currently has 14 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 26912385
  • The evidence classes most visible in the row language are insufficient (6), mechanistic or pharmacological (5), and preliminary human (3). PMID 32386395
  • The study-design language most visible in the row language is Human clinical study (4), Animal study (4), Narrative or expert review (3), and other mapped categories (1). PMID 31407943
  • The repeated topics are Cognition and memory (10), and CB1 (4), which tells the reader where to start opening PubMed and DOI links. PMID 33526107

Start with the research question

Cognition and memory is built from 14 source-backed evidence row(s) and 14 research source(s). The current evidence classes read as insufficient (6), mechanistic or pharmacological (5), and preliminary human (3), and the study-design language most often reads as Human clinical study (4), Animal study (4), Narrative or expert review (3), and other mapped categories (1). PMID 26912385

The row-level question is not simply whether Cognition and memory is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are Cognition and memory (10), and CB1 (4). PMID 36088492

Human evidence 3 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 24639045

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 40368229

Mechanistic evidence 5 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 32381378

Limits and uncertainty 6 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 40734690

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 12373420

Where this page has the most source density

The largest bucket surfaced for this page is Cognition and memory. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is CB1, which gives readers another way to see what the literature repeatedly circles. PMID 26912385

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 36088492

Bucket chapters: what the literature is circling

Cognition and memory

10 research sources 10 rows (461-470) Developed but mixed human research summary: insufficient (6), mechanistic or pharmacological (1), preliminary human (3)

Cognition and memory appears in rows studying Cognition and memory. It currently draws from 10 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 26912385

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 26912385

  • Evidence row 461

    THC studied for Cognition and memory; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: cognition or memory outcomes). PMID 26912385

  • Evidence row 470

    THC studied for Cognition and memory; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: cognition or memory outcomes). PMID 30199388

CB1

3 research sources 3 rows (851-854) Mechanistic research summary: mechanistic or pharmacological (3)

Cognition and memory appears in rows about CB1 mechanisms. It currently draws from 3 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 36088492

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 36088492

  • Evidence row 851

    Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or... PMID 36088492

  • Evidence row 854

    Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, p... PMID 31491589

CB1

1 research source 861 Mechanistic research summary: mechanistic or pharmacological (1)

Cognition and memory appears in rows about CB1 mechanisms. It currently draws from 1 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 36613469

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 36613469

  • Evidence row 861

    Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metaboli... PMID 36613469

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (3 row(s)), mechanistic evidence (5 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 26912385

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 36088492

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 30199388
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 36088492
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 35429587

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 26912385

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 36088492

Source-reading checklist for Cognition and memory

  1. Open the linked PubMed or DOI record. PMID 31491589
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 36613469
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 26912385
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 32386395
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 31407943

Source Notes

Cognition and memory source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 461

    THC studied for Cognition and memory; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: cognition or memory outcomes). PMID 26912385

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids: Medical implications.
  2. Evidence row 462

    THC studied for Cognition and memory; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: cognition or memory outcomes). PMID 32386395

    Evidence class: preliminary human; Study design: Human clinical study. Source: Δ9-Tetrahydrocannabinol (THC) impairs visual working memory performance: a randomized crossover trial.
  3. Evidence row 463

    THC studied for Cognition and memory; evidence class: insufficient (study design: Human clinical study; outcome measure: cognition or memory outcomes). PMID 31407943

    Evidence class: insufficient; Study design: Human clinical study. Source: Developing a phone-based measure of impairment after acute oral ∆9-tetrahydrocannabinol.
  4. Evidence row 464

    THC studied for Cognition and memory; evidence class: insufficient (outcome measure: cognition or memory outcomes). PMID 33526107

    Evidence class: insufficient. Source: Acute effects of naturalistic THC vs. CBD use on recognition memory: a preliminary study.
  5. Evidence row 465

    THC studied for Cognition and memory; evidence class: mechanistic or pharmacological (outcome measure: cognition or memory outcomes). PMID 24639045

    Evidence class: mechanistic or pharmacological. Source: Acute administration of THC impairs spatial but not associative memory function in zebrafish.
  6. Evidence row 466

    THC studied for Cognition and memory; evidence class: insufficient (study design: Systematic review; outcome measure: cognition or memory outcomes). PMID 40368229

    Evidence class: insufficient; Study design: Systematic review. Source: Effects of different methods of cannabis use on cognition and blood THC: A systematic review.
  7. Evidence row 467

    THC studied for Cognition and memory; evidence class: insufficient (study design: Narrative or expert review; outcome measure: cognition or memory outcomes). PMID 32381378

    Evidence class: insufficient; Study design: Narrative or expert review. Source: [Cannabis: Similarities and differences with tobacco].
  8. Evidence row 468

    THC studied for Cognition and memory; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: cognition or memory outcomes). PMID 40734690

    Evidence class: preliminary human; Study design: Human clinical study. Source: The Individual and Interactive Effects of Alpha-Pinene and Delta-9-Tetrahydrocannabinol in Healthy Adults.
  9. Evidence row 469

    THC studied for Cognition and memory; evidence class: preliminary human (study design: Human clinical study; outcome measure: cognition or memory outcomes). PMID 12373420

    Evidence class: preliminary human; Study design: Human clinical study. Source: Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users.
  10. Evidence row 470

    THC studied for Cognition and memory; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: cognition or memory outcomes). PMID 30199388

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The acute effects of cannabis on human executive function.
  11. Evidence row 851

    Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 36088492

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Peripheral CB1 receptor blockade acts as a memory enhancer through a noradrenergic mechanism.
  12. Evidence row 852

    Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 35429587

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Role of the cannabinoid CB1 receptor in methamphetamine-induced social and recognition memory impairment.
  13. Evidence row 854

    Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 31491589

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Adipocyte cannabinoid CB1 receptor deficiency alleviates high fat diet-induced memory deficit, depressive-like behavior, neuroinflammation and impairment in adult neurogenesis.
  14. Evidence row 861

    Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 36613469

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Hippocampal Deletion of CB1 Receptor Impairs Social Memory and Leads to Age-Related Changes in the Hippocampus of Adult Mice.